Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vopratelimab |
Synonyms | |
Therapy Description |
Vopratelimab (JTX-2011) is a humanized monoclonal antibody against ICOS (inducible co-stimulator molecule) that regulates anti-tumor immune response (Cancer Res 2016;76(14 Suppl):Abstract nr 573). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vopratelimab | JTX2011|JTX-2011 | Vopratelimab (JTX-2011) is a humanized monoclonal antibody against ICOS (inducible co-stimulator molecule) that regulates anti-tumor immune response (Cancer Res 2016;76(14 Suppl):Abstract nr 573). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04319224 | Phase Ib/II | Vopratelimab Nivolumab + Vopratelimab Ipilimumab + Vopratelimab | Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | Terminated | USA | 0 |
NCT02904226 | Phase Ib/II | Nivolumab + Vopratelimab Vopratelimab | Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC) | Completed | USA | 0 |